{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:24:20Z","timestamp":1791995060096,"version":"4.4.0"},"reference-count":66,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7_suppl_2","content-domain":{"domain":["neurology.org"],"crossmark-restriction":true},"short-container-title":["Neurology"],"published-print":{"date-parts":[[2006,10,10]]},"DOI":"10.1212\/wnl.67.7_suppl_2.s30","type":"journal-article","created":{"date-parts":[[2012,5,13]],"date-time":"2012-05-13T14:45:05Z","timestamp":1336920305000},"update-policy":"https:\/\/doi.org\/10.1212\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":66,"title":["New pharmacologic horizons in the treatment of Parkinson disease"],"prefix":"10.1212","volume":"67","author":[{"given":"Ubaldo","family":"Bonuccelli","sequence":"first","affiliation":[{"name":"From the Department of Neuroscience, University of Pisa (U.B.) and Neurology Unit, Hospital of Viareggio (P.D.D.), Pisa, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Del Dotto","sequence":"additional","affiliation":[{"name":"From the Department of Neuroscience, University of Pisa (U.B.) and Neurology Unit, Hospital of Viareggio (P.D.D.), Pisa, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(04)00740-9"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-4580(02)00065-9"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10513"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10483"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1990.tb02325.x"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-004-0944-0"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/349414a0"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(199903)14:2<383::AID-MDS1037>3.0.CO;2-F"},{"key":"e_1_3_2_10_2","first-page":"271","year":"2005","unstructured":"Ahlskog JE. Challenging conventional wisdom: the etiologic role of dopamine oxidative stress in Parkinson's disease. Mov Disord 2005;20:271\u2013282.","journal-title":"Mov Disord"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrn1434"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.10148"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199301213280305"},{"key":"e_1_3_2_14_2","first-page":"73","volume":"84","year":"1991","unstructured":"Allain H, Couguard J, Neukirch HC. Selegiline in de novo parkinsonian patients: the French selegiline multicenter trial (FSMT). Acta Neurol Scand 1991;84(suppl 136):73\u201378.","journal-title":"Acta Neurol Scand"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.51.2.520"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(05)70097-1"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270005277935"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.61.4.561"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.59.10.1541"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.1999.7049"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410440206"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410440117"},{"key":"e_1_3_2_23_2","first-page":"494","volume":"58","year":"2002","unstructured":"Jenner P, Iravani M, Haddon C, et al. Pramipexole protects against MPTP-induced nigral dopaminergic cell loss in primates. Neurology 2002;58:494\u2013498.","journal-title":"Neurology"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(99)01688-1"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj20030017"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.13.1653"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10609"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1460-9568.2002.01938.x"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/34651"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10102"},{"key":"e_1_3_2_31_2","first-page":"33","volume":"35","year":"1992","unstructured":"Rojas P, Altagrecia M, Kravsov J, et al. Partially protective effect of amantadine in the MPTP model of Parkinson's disease. Proc West Pharmacol Soc 1992;35:33\u201335.","journal-title":"Proc West Pharmacol Soc"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1602\/neurorx.1.1.101"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-004-0944-0"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.251341998"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/1098-2396(200102)39:2<167::AID-SYN8>3.0.CO;2-U"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.60.8.1059"},{"key":"e_1_3_2_37_2","first-page":"1531","year":"2001","unstructured":"Hurelbrink CB, Barker RA. Prospects for the treatment of Parkinson's disease using neurotrophic factors. Exp Opin Pharmacother 2001;2:1531\u20131543.","journal-title":"Exp Opin Pharmacother"},{"key":"e_1_3_2_38_2","first-page":"583","volume":"9","year":"2003","unstructured":"Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson's disease. Nature Med 2003;9:583\u2013595.","journal-title":"Nature Med"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.60.1.69"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2004.06.016"},{"key":"e_1_3_2_41_2","first-page":"107","volume":"5","year":"2004","unstructured":"Marshall VL, Grosset DG. GPI-1485 (Guilford). Curr Opin Invest Drugs 2004;5:107\u2013112.","journal-title":"Curr Opin Invest Drugs"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.59.12.1937"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000134672.44217.F7"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.60.12.1721"},{"key":"e_1_3_2_45_2","unstructured":"Watts RL Wendt RL Nausied B et al. Efficacy safety and tolerability of the rotigotine transdermal patch in patients with early-stage idiopathic Parkinson's disease: a multicenter multinational randomized double-blind placebo-controlled trial. Mov Disord 2004;19(suppl 9):S258."},{"key":"e_1_3_2_46_2","first-page":"S121","volume":"47","year":"2000","unstructured":"Chase TN, Ho JD. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann Neurol 2000;47(suppl 1):S121\u2013S130.","journal-title":"Ann Neurol"},{"key":"e_1_3_2_47_2","first-page":"919","year":"2005","unstructured":"Brotchie JM. Nondopaminergic mechanisms in levodopa-induced dyskinesias. Mov Disord 2005;20:919\u2013931.","journal-title":"Mov Disord"},{"key":"e_1_3_2_48_2","first-page":"151","year":"2005","unstructured":"Katzenschlager R, Hugles A, Evans A, et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord 2005;20:151\u2013157.","journal-title":"Mov Disord"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000149637.70961.4C"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200105000-00008"},{"key":"e_1_3_2_51_2","first-page":"89","volume":"68","year":"2004","unstructured":"Woitalla D, Muller T, Benz S, Horowski R, Przuntek H. Transdermal lisuride delivery in Parkinson's disease. J Neural Transm 2004;68(suppl):89\u201395.","journal-title":"J Neural Transm"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1007\/s100720200034"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.62.2.241"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71083-7"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20124"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm875"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20120"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2004.01.018"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2004.03.011"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.8.1589"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000081227.84197.0B"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000073136.00548.D4"},{"key":"e_1_3_2_63_2","unstructured":"Lewitt PA US005\/US006 Clinical Investigator Group. \u201cOff\u201d time reduction from adjunctive use of istradephylline (KW-6002) in L-dopa-treated patients with advanced Parkinson's disease. Mov Disord 2004;19(suppl 9):S222."},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.14.6.729"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.10.1829"},{"key":"e_1_3_2_66_2","first-page":"932","year":"2005","unstructured":"Bara-Jimenez W, Bibbiani F, Morris MJ, et al. Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. Mov Disord 2005;20:932\u2013936.","journal-title":"Mov Disord"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200403000-00003"}],"container-title":["Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.neurology.org\/doi\/full\/10.1212\/WNL.67.7_suppl_2.S30","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T16:49:22Z","timestamp":1711644562000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.neurology.org\/doi\/10.1212\/WNL.67.7_suppl_2.S30"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10,10]]},"references-count":66,"journal-issue":{"issue":"7_suppl_2","published-print":{"date-parts":[[2006,10,10]]}},"alternative-id":["10.1212\/WNL.67.7_suppl_2.S30"],"URL":"https:\/\/doi.org\/10.1212\/wnl.67.7_suppl_2.s30","relation":{},"ISSN":["0028-3878","1526-632X"],"issn-type":[{"value":"0028-3878","type":"print"},{"value":"1526-632X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10,10]]}}}